LT3768674T - Aminopirimidino dariniai kaip ctps1 inhibitoriai - Google Patents
Aminopirimidino dariniai kaip ctps1 inhibitoriaiInfo
- Publication number
- LT3768674T LT3768674T LTEPPCT/EP2019/057320T LTEP2019057320T LT3768674T LT 3768674 T LT3768674 T LT 3768674T LT EP2019057320 T LTEP2019057320 T LT EP2019057320T LT 3768674 T LT3768674 T LT 3768674T
- Authority
- LT
- Lithuania
- Prior art keywords
- aminopyrimidine derivatives
- ctps1 inhibitors
- ctps1
- inhibitors
- aminopyrimidine
- Prior art date
Links
- 102100039866 CTP synthase 1 Human genes 0.000 title 1
- 101001101919 Homo sapiens CTP synthase 1 Proteins 0.000 title 1
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18163772.9A EP3543232A1 (en) | 2018-03-23 | 2018-03-23 | Aminopyrimidine derivatives as ctps1 inhibitors |
EP18175823.6A EP3578551A1 (en) | 2018-06-04 | 2018-06-04 | Sulfonamide derivatives |
EP18202136 | 2018-10-23 | ||
PCT/EP2018/086617 WO2019179652A1 (en) | 2018-03-23 | 2018-12-21 | Aminopyrimidine derivatives as ctps1 inhibitors |
PCT/EP2019/057320 WO2019180244A1 (en) | 2018-03-23 | 2019-03-22 | Aminopyrimidine derivatives as ctps1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3768674T true LT3768674T (lt) | 2024-04-25 |
Family
ID=64949297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/EP2019/057320T LT3768674T (lt) | 2018-03-23 | 2019-03-22 | Aminopirimidino dariniai kaip ctps1 inhibitoriai |
Country Status (22)
Country | Link |
---|---|
US (1) | US20210024507A1 (lt) |
EP (1) | EP3768674B1 (lt) |
JP (2) | JP7428692B2 (lt) |
KR (1) | KR102735169B1 (lt) |
CN (1) | CN111868051B (lt) |
AU (1) | AU2018413791B2 (lt) |
BR (1) | BR112020018701A2 (lt) |
CA (1) | CA3093050A1 (lt) |
DK (1) | DK3768674T3 (lt) |
EA (1) | EA202092263A1 (lt) |
ES (1) | ES2974445T3 (lt) |
FI (1) | FI3768674T3 (lt) |
HR (1) | HRP20240375T8 (lt) |
HU (1) | HUE066693T2 (lt) |
IL (1) | IL277455B2 (lt) |
LT (1) | LT3768674T (lt) |
MX (1) | MX2020009887A (lt) |
PH (1) | PH12020500655A1 (lt) |
PL (1) | PL3768674T3 (lt) |
SG (1) | SG11202103238XA (lt) |
SI (1) | SI3768674T1 (lt) |
WO (1) | WO2019179652A1 (lt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3717459A1 (en) | 2017-11-30 | 2020-10-07 | Step Pharma S.A.S. | Compounds |
EP3717465A1 (en) | 2017-11-30 | 2020-10-07 | Step Pharma S.A.S. | Compounds |
WO2020083975A1 (en) * | 2018-10-23 | 2020-04-30 | Step Pharma S.A.S. | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors |
WO2020245665A1 (en) | 2019-06-04 | 2020-12-10 | Step Pharma S.A.S. | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases |
US20220324837A1 (en) * | 2019-06-04 | 2022-10-13 | Step Pharma S.A.S. | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases |
US20230020663A1 (en) | 2019-09-20 | 2023-01-19 | Step Pharma S.A.S. | Sulfonamide inhibitors as ctps1 inhibitors |
WO2021053402A2 (en) | 2019-09-20 | 2021-03-25 | Step Pharma S.A.S. | Compounds |
JP2023546996A (ja) * | 2020-10-23 | 2023-11-08 | ニンバス クロソー, インコーポレイテッド | Ctps1阻害剤およびその使用 |
WO2023166080A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor |
WO2023166077A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy |
WO2023166078A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor |
EP4486347A1 (en) | 2022-03-01 | 2025-01-08 | Step Pharma S.A.S. | Combinations of ctps1 and bcl2 inhibitors for cancer |
WO2024133721A1 (en) | 2022-12-21 | 2024-06-27 | Step Pharma S.A.S. | Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer |
WO2024133730A1 (en) | 2022-12-21 | 2024-06-27 | Step Pharma S.A.S. | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer |
CN118359588A (zh) * | 2023-01-19 | 2024-07-19 | 杭州英创医药科技有限公司 | 作为ctps1抑制剂的化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR056871A1 (es) * | 2005-10-04 | 2007-10-31 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
KR100928203B1 (ko) * | 2007-12-10 | 2009-11-25 | 한국전자통신연구원 | 실리콘 바이오 센서 및 그의 제조 방법 |
AU2008335709A1 (en) * | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
KR101097312B1 (ko) * | 2009-08-10 | 2011-12-23 | 삼성모바일디스플레이주식회사 | 유기 발광 소자 |
JP2016523818A (ja) * | 2013-04-18 | 2016-08-12 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | それを必要とする被験体におけるt細胞増殖を阻害するための方法及び医薬組成物(ctps1阻害剤、例えばノルロイシン) |
GB201322333D0 (en) * | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | WNT pathway modulators |
WO2015170435A1 (ja) * | 2014-05-09 | 2015-11-12 | パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカ | 端末、基地局、送信方法及び受信方法 |
WO2016016370A1 (en) * | 2014-07-31 | 2016-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flt3 receptor antagonists |
-
2018
- 2018-12-21 CN CN201880091502.6A patent/CN111868051B/zh active Active
- 2018-12-21 WO PCT/EP2018/086617 patent/WO2019179652A1/en active Application Filing
- 2018-12-21 IL IL277455A patent/IL277455B2/en unknown
- 2018-12-21 CA CA3093050A patent/CA3093050A1/en active Pending
- 2018-12-21 AU AU2018413791A patent/AU2018413791B2/en active Active
- 2018-12-21 KR KR1020207030329A patent/KR102735169B1/ko active Active
- 2018-12-21 MX MX2020009887A patent/MX2020009887A/es unknown
- 2018-12-21 JP JP2021500333A patent/JP7428692B2/ja active Active
-
2019
- 2019-03-22 ES ES19713022T patent/ES2974445T3/es active Active
- 2019-03-22 HR HRP20240375TT patent/HRP20240375T8/hr unknown
- 2019-03-22 LT LTEPPCT/EP2019/057320T patent/LT3768674T/lt unknown
- 2019-03-22 BR BR112020018701-1A patent/BR112020018701A2/pt unknown
- 2019-03-22 SI SI201930725T patent/SI3768674T1/sl unknown
- 2019-03-22 DK DK19713022.2T patent/DK3768674T3/da active
- 2019-03-22 HU HUE19713022A patent/HUE066693T2/hu unknown
- 2019-03-22 EA EA202092263A patent/EA202092263A1/ru unknown
- 2019-03-22 US US16/982,641 patent/US20210024507A1/en not_active Abandoned
- 2019-03-22 EP EP19713022.2A patent/EP3768674B1/en active Active
- 2019-03-22 PL PL19713022.2T patent/PL3768674T3/pl unknown
- 2019-03-22 SG SG11202103238XA patent/SG11202103238XA/en unknown
- 2019-03-22 FI FIEP19713022.2T patent/FI3768674T3/fi active
-
2020
- 2020-08-27 PH PH12020500655A patent/PH12020500655A1/en unknown
-
2023
- 2023-10-19 JP JP2023180542A patent/JP2024020222A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HRP20240375T1 (hr) | 2024-06-07 |
PH12020500655A1 (en) | 2021-06-21 |
JP2021518436A (ja) | 2021-08-02 |
IL277455B2 (en) | 2024-05-01 |
JP7428692B2 (ja) | 2024-02-06 |
EA202092263A1 (ru) | 2021-01-15 |
SG11202103238XA (en) | 2021-04-29 |
ES2974445T3 (es) | 2024-06-27 |
FI3768674T3 (fi) | 2024-04-02 |
BR112020018701A2 (pt) | 2020-12-29 |
HUE066693T2 (hu) | 2024-08-28 |
MX2020009887A (es) | 2020-10-12 |
EP3768674A1 (en) | 2021-01-27 |
SI3768674T1 (sl) | 2024-05-31 |
DK3768674T3 (da) | 2024-02-19 |
HRP20240375T8 (hr) | 2024-06-21 |
AU2018413791B2 (en) | 2023-05-18 |
IL277455A (en) | 2020-11-30 |
WO2019179652A1 (en) | 2019-09-26 |
US20210024507A1 (en) | 2021-01-28 |
AU2018413791A1 (en) | 2020-09-17 |
CN111868051B (zh) | 2024-04-09 |
KR20200135463A (ko) | 2020-12-02 |
KR102735169B1 (ko) | 2024-11-26 |
EP3768674B1 (en) | 2024-01-03 |
PL3768674T3 (pl) | 2024-04-29 |
IL277455B1 (en) | 2024-01-01 |
JP2024020222A (ja) | 2024-02-14 |
CA3093050A1 (en) | 2019-09-26 |
CN111868051A (zh) | 2020-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT3768674T (lt) | Aminopirimidino dariniai kaip ctps1 inhibitoriai | |
MA54543A (fr) | Inhibiteurs de kif18a | |
MA54550A (fr) | Inhibiteurs de kif18a | |
EP3898592C0 (en) | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | |
EP3898616C0 (en) | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | |
HUE062096T2 (hu) | Piridazinonok PARP7-inhibitorokként | |
DK3601239T3 (da) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
PL3870574T3 (pl) | Pochodne aminopirymidyny/pirazyny jako inhibitory CTPS1 | |
MA52812A (fr) | Inhibiteurs de sarm1 | |
DK3571192T3 (da) | Jak1-selektive inhibitorer | |
EP3817736A4 (en) | PIKFYVE INHIBITORS | |
LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
EP3801500A4 (en) | INHIBITORS OF SARM1 | |
MA52809A (fr) | Inhibiteurs de sarm1 | |
DK3768669T3 (da) | Piperazinazaspiroderivater | |
EP3884940A4 (en) | Novel imidazole derivative | |
DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
EP3615525C0 (en) | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | |
EP4013751C0 (en) | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | |
EP3600301A4 (en) | KDM4 INHIBITORS | |
DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
DK3894410T3 (da) | Substituerede xanthinderivater |